Skip to content
2000
image of Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study

Abstract

Introduction

Treatment-resistant depression (TRD) is a severe psychiatric condition that may increase the risk of suicidal thoughts and self-harming behaviors. Intranasal esketamine has emerged as an effective treatment for TRD, also addressing depression-related emergencies such as suicidal ideation.

Methods

This retrospective observational study analyzed 26 outpatients with TRD treated with adjunctive intranasal esketamine alongside ongoing oral antidepressants for 4 weeks. Suicidal ideation and behaviors were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), and depressive symptoms were evaluated with the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline, week 2, and week 4. Statistical analyses included repeated-measures ANOVA and subgroup analyses by gender and baseline self-harm profile.

Results

Esketamine significantly reduced suicidal ideation and depressive symptoms from baseline to week 2 and week 4 (all <.001). Additionally, non-suicidal self-harm declined, exhibiting gender-specific patterns: women demonstrated a faster reduction in non-suicidal self-harm, whereas men showed slower improvement in suicidal self-harm. A strong correlation between depressive symptoms and suicidality confirmed their interplay.

Discussion

In our real-world TRD sample, adjunctive intranasal esketamine led to a rapid and sustained reduction in suicidality and depressive symptoms, with distinct gender-related patterns in self-harm trajectories. These findings may inform individualized monitoring strategies. Limitations include the small sample size, retrospective design, and lack of a control group.

Conclusion

Esketamine rapidly improved suicidality and depression in TRD, with preliminary evidence suggesting gender-specific responses, and highlighting the importance of tailored interventions to maximize outcomes. Further research is needed to confirm these differences, explore the long-term effects, and understand the underlying mechanisms.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X392347250929114024
2025-10-20
2025-12-18

  • From This Site

    /content/journals/cn/10.2174/011570159X392347250929114024
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McIntyre R.S. Carvalho I.P. Lui L.M.W. Majeed A. Masand P.S. Novel interventions for treatment-resistant depression: Mechanisms and evidence. Lancet Psychiatry 2024 11 1 50 62 10.1016/S2215‑0366(23)00398‑4
    [Google Scholar]
  2. Kasper S. Dold M. Lanzenberger R. Lamm C. Treatment-resistant depression: New approaches in augmentative strategies. World J. Biol. Psychiatry 2021 22 1 18 34 10.1080/15622975.2020.1795117
    [Google Scholar]
  3. Lengvenyte A. Courtet P. Guillaume S. The role of childhood trauma in treatment-resistant depression and suicidality. Psychiatry Res. 2022 307 114336 10.1016/j.psychres.2021.114336
    [Google Scholar]
  4. Martiadis V. Demyttenaere K. Martinotti G. Fiorillo A. Treatment resistant depression (TRD): Epidemiology, clinic, burden and treatment. Frontiers Media SA Lausanne 2025 10.3389/978‑2‑8325‑6293‑2
    [Google Scholar]
  5. Nemeroff C.B. Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry 2007 68 17 25 17640154
    [Google Scholar]
  6. Zhdanava M. Pilon D. Ghelerter I. Chow W. Joshi K. Lefebvre P. Sheehan J.J. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J. Clin. Psychiatry 2021 82 2 20m13699 10.4088/JCP.20m13699
  7. Thomas L. Kessler D. Campbell J. Morrison J. Peters T.J. Williams C. Lewis G. Wiles N. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br. J. Gen. Pract. 2013 63 617 e852 e858 10.3399/bjgp13X675430 24351501
    [Google Scholar]
  8. Mignon L. Stahl S.M. Clinical management of major depressive disorder. CNS Spectr. 2009 14 S10 3 6 10.1017/S1092852900003837 20173690
    [Google Scholar]
  9. Rosenzweig M.H. Amsterdam J.D. Treatment-resistant depression: Additional perspectives. J. Psychopharmacol. 1992 6 2 167 171 10.1177/026988119200600208 22291347
    [Google Scholar]
  10. Dunner D.L. Rush A.J. Russell J.M. Burke M. Woodard S. Wingard P. Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J. Clin. Psychiatry 2006 67 5 688 695 10.4088/JCP.v67n0501 16841617
    [Google Scholar]
  11. Olchanski N. McInnis Myers M. Halseth M. Cyr P.L. Bockstedt L. Goss T.F. Howland R.H. The economic burden of treatment-resistant depression. Clin. Ther. 2013 35 4 512 522 10.1016/j.clinthera.2012.09.001 23490291
    [Google Scholar]
  12. Canuso C.M. Singh J.B. Fedgchin M. Alphs L. Lane R. Lim P. Pinter C. Hough D. Sanacora G. Manji H. Drevets W.C. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 2018 175 7 620 630 10.1176/appi.ajp.2018.17060720 29656663
    [Google Scholar]
  13. Ionescu D.F. Fu D.J. Qiu X. Lane R. Lim P. Kasper S. Hough D. Drevets W.C. Manji H. Canuso C.M. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a phase 3, double-blind, randomized study (ASPIRE II). Int. J. Neuropsychopharmacol. 2021 24 1 22 31 10.1093/ijnp/pyaa068 32861217
    [Google Scholar]
  14. Reutfors J. Andersson T.M.L. Tanskanen A. DiBernardo A. Li G. Brandt L. Brenner P. Risk factors for suicide and suicide attempts among patients with treatment-resistant depression: Nested case-control study. Arch. Suicide Res. 2021 25 3 424 438 10.1080/13811118.2019.1691692 31774374
    [Google Scholar]
  15. Corral R. Alessandria H. Agudelo Baena L.M. Ferro E. Duque X. Quarantini L. Caldieraro M.A. Cabrera P. Kanevsky G. Suicidality and quality of life in treatment-resistant depression patients in Latin America: Secondary interim analysis of the TRAL study. Front. Psychiatry 2022 13 812938 10.3389/fpsyt.2022.812938 35308889
    [Google Scholar]
  16. Döme P. Kunovszki P. Takács P. Fehér L. Balázs T. Dede K. Mulhern-Haughey S. Barbreau S. Rihmer Z. Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis. PLoS One 2021 16 1 e0245510 10.1371/journal.pone.0245510 33471854
    [Google Scholar]
  17. Brent D.A. Emslie G.J. Clarke G.N. Asarnow J. Spirito A. Ritz L. Vitiello B. Iyengar S. Birmaher B. Ryan N.D. Zelazny J. Onorato M. Kennard B. Mayes T.L. DeBar L.L. McCracken J.T. Strober M. Suddath R. Leonard H. Porta G. Keller M.B. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am. J. Psychiatry 2009 166 4 418 426 10.1176/appi.ajp.2008.08070976 19223438
    [Google Scholar]
  18. Olfson M. Wall M. Wang S. Crystal S. Gerhard T. Blanco C. Suicide following deliberate self-harm. Am. J. Psychiatry 2017 174 8 765 774 10.1176/appi.ajp.2017.16111288 28320225
    [Google Scholar]
  19. Murphy E. Kapur N. Webb R. Purandare N. Hawton K. Bergen H. Waters K. Cooper J. Risk factors for repetition and suicide following self-harm in older adults: multicentre cohort study. Br. J. Psychiatry 2012 200 5 399 404 10.1192/bjp.bp.111.094177 22157801
    [Google Scholar]
  20. Nobile B. Gourguechon-Buot E. Malestroit M. Olié E. Haffen E. Gorwood P. Courtet P. Does depression with current suicidal ideation lead to treatment-resistant depression? Two large naturalistic cohorts of outpatients with depression and current suicidal ideation. Psychiatry Res. 2024 342 116249 10.1016/j.psychres.2024.116249 39488946
    [Google Scholar]
  21. Oquendo M.A. Kamali M. Ellis S.P. Grunebaum M.F. Malone K.M. Brodsky B.S. Sackeim H.A. Mann J.J. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: A prospective study. Am. J. Psychiatry 2002 159 10 1746 1751 10.1176/appi.ajp.159.10.1746 12359682
    [Google Scholar]
  22. Courtet P. Jaussent I. Lopez-Castroman J. Gorwood P. Poor response to antidepressants predicts new suicidal ideas and behavior in depressed outpatients. Eur. Neuropsychopharmacol. 2014 24 10 1650 1658 10.1016/j.euroneuro.2014.07.007 25112546
    [Google Scholar]
  23. Hawton K. Witt K.G. Taylor Salisbury T.L. Arensman E. Gunnell D. Hazell P. Townsend E. van Heeringen K. Pharmacological interventions for self-harm in adults. Cochrane Database Syst. Rev. 2015 2015 7 CD011777 26147958
    [Google Scholar]
  24. Popova V. Daly E.J. Trivedi M. Cooper K. Lane R. Lim P. Hough D. Manji H. Drevets W.C. Efficacy and safety of esketamine nasal spray in treatment-resistant depression: A randomized, double-blind, active-controlled study. Am. J. Psychiatry 2019 176 6 428 438 10.1176/appi.ajp.2019.19020172 31109201
    [Google Scholar]
  25. Reif A. Juckel G. Mössner R. Bauer M. Esketamine as a fast-acting treatment in patients with major depressive disorder: A systematic review and meta-analysis. Psychopharmacology (Berl.) 2023 240 5 1259 1274
    [Google Scholar]
  26. Fu D.J. Ionescu D.F. Li X. Zhang Y. Papadakis S. Sanacora G. Drevets W.C. Manji H. Canuso C.M. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: Results of a phase 3, double-blind, randomized study (ASPIRE II). Int. J. Neuropsychopharmacol. 2020 23 10 571 582
    [Google Scholar]
  27. Canuso C.M. Ionescu D.F. Li X. Qiu X. Lane R. Turkoz I. Nash A.I. Lopena T.J. Fu D.J. Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. J. Clin. Psychopharmacol. 2021 41 5 516 524 10.1097/JCP.0000000000001465 34412104
    [Google Scholar]
  28. Hawton K. Saunders K.E.A. O’Connor R.C. Self-harm and suicide in adolescents. Lancet 2012 379 9834 2373 2382 10.1016/S0140‑6736(12)60322‑5 22726518
    [Google Scholar]
  29. Miranda-Mendizabal A. Castellví P. Parés-Badell O. Alayo I. Almenara J. Alonso I. Blasco M.J. Cebrià A. Gabilondo A. Gili M. Lagares C. Piqueras J.A. Rodríguez-Jiménez T. Rodríguez-Marín J. Roca M. Soto-Sanz V. Vilagut G. Alonso J. Gender differences in suicidal behavior in adolescents and young adults: systematic review and meta-analysis of longitudinal studies. Int. J. Public Health 2019 64 2 265 283 10.1007/s00038‑018‑1196‑1 30635683
    [Google Scholar]
  30. Wilkinson S.T. Ballard E.D. Bloch M.H. Mathew S.J. Murrough J.W. Feder A. Sos P. Wang G. Zarate C.A. Sanacora G. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am. J. Psychiatry 2018 175 2 150 158 10.1176/appi.ajp.2017.17040472 28969441
    [Google Scholar]
  31. Wajs E. Aluisio L. Holder R. Daly E.J. Lane R. Lim P. George J.E. Morrison R.L. Sanacora G. Young A.H. Kasper S. Sulaiman A.H. Li C.T. Paik J.W. Manji H. Hough D. Grunfeld J. Jeon H.J. Wilkinson S.T. Drevets W.C. Singh J.B. Esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study. J. Clin. Psychiatry 2020 81 3 364 372 10.4088/JCP.19m12891 32316080
    [Google Scholar]
  32. Posner K. Brown G.K. Stanley B. Brent D.A. Yershova K.V. Oquendo M.A. Currier G.W. Melvin G.A. Greenhill L. Shen S. Mann J.J. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 2011 168 12 1266 1277 10.1176/appi.ajp.2011.10111704 22193671
    [Google Scholar]
  33. Montgomery S.A. Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979 134 4 382 389 10.1192/bjp.134.4.382 444788
    [Google Scholar]
  34. Nilsson M.E. Suryawanshi S. Gassmann-Mayer C. Dubrava S. McSorley P. Jiang K. Columbia-Suicide Severity Rating Scale scoring and data analysis guide. CSSRS Scoring Version. 2013 2 1 13
    [Google Scholar]
  35. Chronic depression is more often reported by women and increases with age in EU countries. Health at a Glance: Europe. 2018 Available from: https://www.oecd-ilibrary.org/
  36. Terranova C. Trends and methods of suicide in Italy, 1979 to 2016. SAGE Open 2022 12 2 10.1177/21582440221089952
    [Google Scholar]
  37. Müller M. Himmerich H. Kienzle B. Szegedi A. Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS). J. Affect. Disord. 2003 77 3 255 260 10.1016/S0165‑0327(02)00120‑9 14612225
    [Google Scholar]
  38. Corral M. Álvarez A.S. Martí-Navarro M. Martínez-Aran A. Vieta E. Suicide risk in treatment-resistant depression: A narrative review of current evidence. J. Affect. Disord. 2022 296 80 90
    [Google Scholar]
  39. Hantouche E.G. Akiskal H.S. Lancrenon S. Allilaire J.F. Sechter D. Azorin J.M. Bourgeois M. Fraisse J. Chatenet-Duchene L. Lancrenon J. Systematic clinical methodology for validating bipolar-II disorder: Data in mid-stream from a French national multi-site study (EPIDEP). J. Affect. Disord. 2010 84 1 21 27 9858076
    [Google Scholar]
  40. Daly E.J. Trivedi M.H. Janik A. Li H. Zhang Y. Li X. Lane R. Lim P. Duca A.R. Hough D. Manji H. Drevets W.C. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 2018 75 2 139 148 10.1001/jamapsychiatry.2017.3739 29282469
    [Google Scholar]
  41. Zalsman G. Hawton K. Wasserman D. van Heeringen K. Arensman E. Sarchiapone M. Carli V. Höschl C. Barzilay R. Balazs J. Purebl G. Kahn J.P. Sáiz P.A. Lipsicas C.B. Bobes J. Cozman D. Hegerl U. Zohar J. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 2016 3 7 646 659 10.1016/S2215‑0366(16)30030‑X 27289303
    [Google Scholar]
  42. Abdallah C.G. Roache J.D. Gueorguieva R. Averill L.A. Young-McCaughan S. Shiroma P.R. Purohit P. Brundige A. Murff W. Ahn K.H. Sherif M.A. Baltutis E.J. Ranganathan M. D’Souza D. Martini B. Southwick S.M. Petrakis I.L. Burson R.R. Guthmiller K.B. López-Roca A.L. Lautenschlager K.A. McCallin J.P. Hoch M.B. Timchenko A. Souza S.E. Bryant C.E. Mintz J. Litz B.T. Williamson D.E. Keane T.M. Peterson A.L. Krystal J.H. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 2022 47 8 1574 1581 10.1038/s41386‑022‑01266‑9 35046508
    [Google Scholar]
  43. Martinotti G. Vita A. Fagiolini A. Maina G. Bertolino A. Dell’Osso B. Siracusano A. Clerici M. Bellomo A. Sani G. d’Andrea G. Chiaie R.D. Conca A. Barlati S. Di Lorenzo G. De Fazio P. De Filippis S. Nicolò G. Rosso G. Valchera A. Nucifora D. Di Mauro S. Bassetti R. Martiadis V. Olivola M. Belletti S. Andriola I. Di Nicola M. Pettorruso M. McIntyre R.S. di Giannantonio M. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). J. Affect. Disord. 2022 319 646 654 10.1016/j.jad.2022.09.043 36167246
    [Google Scholar]
  44. Rosso G. d’Andrea G. Barlati S. Di Nicola M. Andriola I. Marcatili M. Martiadis V. Olivola M. Di Mauro S. Di Salvo G. De Fazio P. Clerici M. Dell’Osso B.M. Vita A. Di Lorenzo G. Pettorruso M. Martinotti G. Maina G. Esketamine treatment trajectory of patients with treatment-resistant depression in the mid and long-term run: Data from REAL-ESK study group. Curr. Neuropharmacol. 2025 23 5 e1570159X337670 10.2174/011570159X337670241029062524
    [Google Scholar]
  45. Kudielka B.M. Kirschbaum C. Sex differences in HPA axis responses to stress: A review. Biol. Psychol. 2005 69 1 113 132 10.1016/j.biopsycho.2004.11.009 15740829
    [Google Scholar]
  46. Sanacora G. Frye M.A. McDonald W. Mathew S.J. Turner M.S. Schatzberg A.F. Summergrad P. Nemeroff C.B. Meyers B.S. Mallinckrodt C. Manji H.K. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017 74 4 399 405 10.1001/jamapsychiatry.2017.0080 28249076
    [Google Scholar]
  47. Krystal J.H. Charney D.S. Duman R.S. A new rapid-acting antidepressant. Cell 2020 181 1 7 10.1016/j.cell.2020.02.033 32243798
    [Google Scholar]
  48. Mann J.J. Michel C.A. Auerbach R.P. Improving suicide prevention through evidence-based strategies: A systematic review. Am. J. Psychiatry 2021 178 7 611 624 10.1176/appi.ajp.2020.20060864 33596680
    [Google Scholar]
  49. Bresin K. Gordon K.H. Endogenous opioids and nonsuicidal self-injury: A mechanism of affect regulation. Neurosci. Biobehav. Rev. 2013 37 3 374 383 10.1016/j.neubiorev.2013.01.020 23339875
    [Google Scholar]
  50. Joiner T.E. Brown J.S. Wingate L.R. The psychology and neurobiology of suicidal behavior. Annu. Rev. Psychol. 2005 56 1 287 314 10.1146/annurev.psych.56.091103.070320 15709937
    [Google Scholar]
  51. Favaretto E. Bedani F. Brancati G.E. De Berardis D. Giovannini S. Scarcella L. Martiadis V. Martini A. Pampaloni I. Perugi G. Pessina E. Raffone F. Ressico F. Cattaneo C.I. Synthesising 30 years of clinical experience and scientific insight on affective temperaments in psychiatric disorders: State of the art. J. Affect. Disord. 2024 362 406 415 10.1016/j.jad.2024.07.011 38972642
    [Google Scholar]
  52. Nock M.K. Self-Injury. Annu. Rev. Clin. Psychol. 2010 6 1 339 363 10.1146/annurev.clinpsy.121208.131258 20192787
    [Google Scholar]
  53. Arnone D. Karmegam S.R. Östlundh L. Alkhyeli F. Alhammadi L. Alhammadi S. Alkhoori A. Selvaraj S. Risk of suicidal behavior in patients with major depression and bipolar disorder: A systematic review and meta-analysis of registry-based studies. Neurosci. Biobehav. Rev. 2024 159 105594 10.1016/j.neubiorev.2024.105594 38368970
    [Google Scholar]
  54. Linehan M.M. Cognitive-behavioral treatment of borderline personality disorder. New York Guilford Press 1992
    [Google Scholar]
  55. Mahalik J.R. Burns S.M. Syzdek M. Masculinity and perceived normative health behaviors as predictors of men’s health behaviors. Soc. Sci. Med. 2007 64 11 2201 2209 10.1016/j.socscimed.2007.02.035 17383784
    [Google Scholar]
  56. Eisenlohr-Moul T.A. DeWall C.N. Girdler S.S. Segerstrom S.C. Ovarian hormones and borderline personality disorder features: Preliminary evidence for interactive effects of estradiol and progesterone. Biol. Psychol. 2015 109 37 52 10.1016/j.biopsycho.2015.03.016 25837710
    [Google Scholar]
  57. Courtenay W.H. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc. Sci. Med. 2000 50 10 1385 1401 10.1016/S0277‑9536(99)00390‑1 10741575
    [Google Scholar]
  58. Hawton K. Harriss L. Deliberate self-harm in young people: Characteristics and subsequent mortality in a 20-year cohort of patients presenting to hospital. J. Clin. Psychiatry 2007 68 10 1574 1583 10.4088/JCP.v68n1017 17960975
    [Google Scholar]
  59. Bangasser D.A. Wiersielis K.R. Sex differences in stress responses: A critical role for corticotropin-releasing factor. Hormones (Athens) 2018 17 1 5 13 10.1007/s42000‑018‑0002‑z 29858858
    [Google Scholar]
  60. Tang Y. Kong L. Wu F. Womer F. Jiang W. Cao Y. Ren L. Wang J. Fan G. Blumberg H.P. Xu K. Wang F. Decreased functional connectivity between the amygdala and the left ventral prefrontal cortex in treatment-naive patients with major depressive disorder: A resting-state functional magnetic resonance imaging study. Psychol. Med. 2013 43 9 1921 1927 10.1017/S0033291712002759 23194671
    [Google Scholar]
  61. Wu Y. Li H. Zhou Y. Yu J. Zhang Y. Song M. Qin W. Yu C. Jiang T. Sex-specific neural circuits of emotion regulation in the centromedial amygdala. Sci. Rep. 2016 6 1 23112 10.1038/srep23112 27004933
    [Google Scholar]
  62. Edwards M.J. Holden R.R. Coping, meaning in life, and suicidal manifestations: Examining gender differences. J. Clin. Psychol. 2001 57 12 1517 1534 10.1002/jclp.1114 11745593
    [Google Scholar]
  63. Kim S.M. Han D.H. Trksak G.H. Lee Y.S. Gender differences in adolescent coping behaviors and suicidal ideation: Findings from a sample of 73,238 adolescents. Anxiety Stress Coping 2014 27 4 439 454 10.1080/10615806.2013.876010 24344782
    [Google Scholar]
  64. Di Nicola M. Pepe M. d’Andrea G. Marcelli I. Pettorruso M. Andriola I. Barlati S. Carminati M. Cattaneo C.I. Clerici M. De Berardis D. De Filippis S. Dell’Osso B. Di Lorenzo G. Maina G. Manchia M. Marcatili M. Martiadis V. Niolu C. Petralia A. Rosso G. Serafini G. Signorelli M.S. Vannucchi T. Vismara M. Zanardi R. Vita A. Sani G. Martinotti G. Patient experience with intranasal esketamine in treatment-resistant depression: Insights from a multicentric Italian study (REAL-ESKperience). J. Pers. Med. 2025 15 4 161 10.3390/jpm15040161 40278340
    [Google Scholar]
  65. Di Vincenzo M. Martiadis V. Della Rocca B. Arsenio E. D’Arpa A. Volpicelli A. Luciano M. Sampogna G. Fiorillo A. Facts and myths about use of esketamine for treatment-resistant depression: A narrative clinical review. Front. Psychiatry 2024 15 1394787 10.3389/fpsyt.2024.1394787 38812489
    [Google Scholar]
  66. Perrone V. Sangiorgi D. Andretta M. Ducci G. Forti B. Francesa Morel P.C. Gambera M. Maina G. Mencacci C. Mennini F.S. Zanalda E. Degli E.L. Healthcare resource consumption and related costs of patients estimated with treatment-resistant depression in Italy. Clinicoecon. Outcomes Res. 2021 13 629 635 10.2147/CEOR.S314111 34262308
    [Google Scholar]
  67. AlAzzam M. Abuhammad S. Tawalbeh L. Dalky H. Prevalence and correlates of depression, anxiety, and suicidality among high school students: A national study. J. Psychosoc. Nurs. Ment. Health Serv. 2021 59 8 43 51 10.3928/02793695‑20210426‑02 34110946
    [Google Scholar]
  68. AlAzzam M. Abuhammad S. Abdalrahim A. Hamdan-Mansour A.M. Predictors of depression and anxiety among senior high school students during COVID-19 pandemic: The context of home quarantine and online education. J. Sch. Nurs. 2021 37 4 241 248 10.1177/1059840520988548 33563066
    [Google Scholar]
/content/journals/cn/10.2174/011570159X392347250929114024
Loading
Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study
Bentham Science Publishers ; https://doi.org/10.2174/011570159X392347250929114024
/content/journals/cn/10.2174/011570159X392347250929114024
/content/journals/cn/10.2174/011570159X392347250929114024
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: suicide ; gender differences ; TRD ; suicidal ideation ; efficacy ; Esketamine ; self-harm ; depression ; major depressive disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test